Previous 10 | Next 10 |
home / stock / alt / alt articles
BENSALEM, Pa., May 24, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on b...
SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and ...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmu...
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investo...
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Comp...
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmun...
The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Comp...
LOS ANGELES, May 17, 2024 (GLOBE NEWSWIRE) -- Los Angeles -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have ...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) Toronto, Canada and Lima, Peru – TheNewswire - July 15, 2024 – Alturas Minerals Corp. (the “Company”) (TSX-V, BVL: ALT) is pleased to provide an update on the Lease agreement with Sociedad Contractual Minera Resguardo (“Minera...
2024-07-11 10:45:04 ET Rivian Automotive Inc (RIVN) RIVN is trading UP for the last 5 days, and it at trading at $16.74 with volume of 18,885,597 and a one day change of $0.37 (2.23%). Rivian Automotive Inc has a 52-week low of 12.15 and a 52-week high of $32.60. The business's 50-d...
2024-07-10 06:41:00 ET Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) are a pair of biotechs planning to follow in the footsteps of Novo Nordisk and Eli Lilly and develop GLP-1-targeted medicines for obesity like Wegovy and Zepbound. Both companies ha...